Tailored Immunotherapy Approach With Nivolumab in Advanced Transitional Cell Carcinoma.
Marc-Oliver GrimmBernd Jürgen Schmitz-DrägerUwe ZimmermannChristine Barbara GrünGustavo Bruno BarettonMarc SchmitzSusan FollerKatharina LeuchtMartin SchostakFriedemann ZengerlingUlrike SchumacherWolfgang LoidlJohannes MeranPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
The tailored approach of TITAN-TCC shows meaningful clinical activity supporting dual checkpoint inhibition in 1L mUC. However, starting therapy with nivolumab exclusively appears inadequate given the aggressive nature of mUC. In 2/3L, nivolumab/ipilimumab boosts with escalating ipilimumab dose did not improve efficacy outcomes versus nivolumab monotherapy. An independent 2L cohort of TITAN-TCC receiving nivolumab 1 mg/kg plus ipilimumab 3 mg/kg once every 3 weeks for 4 doses is ongoing.